The Medicare GLP-1 Bridge, Explained: Eligibility, Structure, and Sunset Date

On July 1, 2026, the Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge — a short-term demonstration program giving eligible Medicare Part D beneficiaries access to certain GLP-1 medications through a mechanism separate from standard Part D coverage.[1] The program has generated significant coverage as a policy shift, but much of that coverage summarizes the outcome without detailing the legal structure underneath it. Here's what the source documents actually establish.

Legal authority

The program operates under Section 402(a)(1)(A) of the Social Security Amendments of 1967, as amended, and made applicable to Medicare Part D by Section 1860D-42(b) of the Social Security Act.[1] That authority permits the HHS Secretary to run demonstration projects testing whether changes in payment or reimbursement methods would increase the efficiency and economy of Medicare-covered health services, through the creation of additional incentives toward those ends. In practical terms, this is the same broad demonstration-project authority CMS has used for a range of prior payment pilots — it does not require new legislation, which is part of why the program could launch on a defined date rather than moving through a full legislative process.

Structure

• Duration: July 1, 2026 through December 31, 2027 — a fixed demonstration window, not an open-ended benefit change
• Coverage flow: The Bridge operates outside the standard Medicare Part D benefit's coverage and payment flow, rather than being folded into existing Part D plan structures
• Plan sponsor participation: Part D plan sponsors do not carry financial risk for GLP-1 drugs furnished under the Bridge, and sponsors are not required to opt in for the program to apply to their beneficiaries
• Claims processing: CMS uses a single, centralized processor to manage prior authorization, claims adjudication, and pharmacy payment for the program in 2026, rather than routing through each individual Part D sponsor's existing infrastructure

Why a centralized processor, specifically

Routing prior authorization, claims adjudication, and pharmacy payment through a single processor — rather than each Part D sponsor's own system — is a structural choice that simplifies data collection for CMS. Since the stated statutory purpose is testing whether a payment change increases efficiency, centralized processing gives CMS a cleaner, more uniform dataset to evaluate the demonstration against by the time it concludes, compared to reconciling data across dozens of separate sponsor systems.

Prior authorization timing

CMS published a prior authorization form ahead of the launch date for informational purposes, but explicitly did not accept or process prior authorization requests before July 1, 2026. The form was updated with a submission fax number effective on the launch date itself — a detail that matters for anyone who attempted to submit paperwork early expecting it to be processed retroactively.

What remains unclear from the source documents

Policy context

The Bridge's launch is closely tied to the broader Medicare telehealth flexibility extension through December 31, 2027, signed into law via the Consolidated Appropriations Act, 2026 in February 2026.[2] The two policies share an end date and, functionally, the telehealth flexibilities are part of the delivery infrastructure that makes Bridge-covered prescriptions practically accessible for a meaningful share of the Medicare population who don't have a local prescriber offering this option in person.